The optimal management strategy for adults with immune-tolerant (IT) chronic hepatitis B infection remains undefined. This ...
High baseline HAI score. Antiviral therapy can prevent or reduce fibrosis progression. Thus, even when baseline ALT is not high, if the liver biopsy results indicate severe disease, treatment is ...
Researchers evaluated pegylated interferon-alpha (Peg-IFN-α) therapy in patients with Child-Pugh class A cirrhosis and found no higher risk of liver decompensation or severe adverse events compared to ...
The rate of functional cure (HBsAg loss) remains unsatisfactory following pegylated interferon (PEG-IFN) treatment in chronic hepatitis B. To optimize PEG-IFN administration, this study aimed to ...
HBsAg decline at week 24 and baseline HBsAg levels are better predictors of functional cure than novel virologic markers, while on-treatment HBV RNA and HBeAg levels and dynamic changes are the most ...
Please provide your email address to receive an email when new articles are posted on . Among patients with low baseline HBsAg, 39% achieved HBsAg loss with tobevibart/elebsiran, which rose to 46% ...
Please provide your email address to receive an email when new articles are posted on . The highest percentages of patients with HBsAg loss were observed in the groups that received xalnesiran plus an ...
In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...
Treatment with the investigational drug bulevirtide plus pegylated interferon alfa-2a (PegIFNα) resulted in more patients achieving undetectable levels of hepatitis D virus (HDV) RNA compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results